Furthermore, similar results from UALCAN showed that EOGT expression was significantly upregulated in head and neck squamous cell carcinoma (HNSC), thyroid carcinoma (THCA), kidney renal clear cell carcinoma (KIRC), cholangiocarcinoma (CHOL), and HCC and was markedly downregulated in bladder urothelial carcinoma (BLCA), lung squamous cell carcinoma (LUSC), uterine corpus endometrial carcinoma (UCEC), lung adenocarcinoma (LUAD), kidney chromophobe (KICH), breast-invasive carcinoma (BRCA), and prostate adenocarcinoma (PRAD) (Figure 1I and Supplementary Figure 1). Here, EOGT is linked to bladder transitional cell carcinoma.